Physician profile
Antoune G Saad
NPI 1679587067
$5,088.67
in general payments reported to CMS, 2019-2025
27 companies · $620 in 2025
The $620 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $567 · 2021: $643 · 2022: $834 · 2023: $792 · 2024: $914 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,326.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $675.49 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $654.71 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Corium, LLC | $589.53 | 2023-2025 | Azstarys |
| Tris Pharma INC | $539.17 | 2019-2023 | Dyanavel Xr |
| Cranial Technologies, INC | $354.03 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $304.10 | 2020-2024 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $224.73 | 2020-2022 | |
| Sobi, INC | $219.93 | 2019-2023 | |
| Adlon Therapeutics L.P. | $184.28 | 2020-2021 | |
| Sanofi Pasteur INC. | $176.17 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $166.98 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $155.75 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $125.66 | 2025 | Neffy |
| Kaleo, INC. | $115.55 | 2019-2024 | Auvi-Q |
| Phadia US INC. | $104.89 | 2022-2024 | Immunocap |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $92.10 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $80.84 | 2024-2025 | Zoryve |
| Astrazeneca Pharmaceuticals Lp | $62.89 | 2023-2024 | Flumist Quadrivalent |
| Alexion Pharmaceuticals, INC. | $51.02 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $50.56 | 2024 | Ycanth |
| Xeris Pharmaceuticals, INC. | $29.18 | 2022 | |
| Alk-Abello, INC | $27.39 | 2025 | Neffy |
| Lilly USA, LLC | $26.92 | 2024 | Jardiance, Zepbound |
| Regeneron Healthcare Solutions, INC. | $25.18 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $23.42 | 2025 | |
| Lnhc, INC | $17.09 | 2025 | Zelsuvmi |
| Aytu Biopharma, INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoune Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.